Johnson & Johnson bullish on 2026 outlook after deal with US administration

Johnson & Johnson employs more than 6,000 people in Ireland

Johnson & Johnson’s fourth-quarter sales beat expectations, led by strong growth for several newer cancer treatments. Sales are projected to be in a range of between $100bn to €101bn (€85bn to €86bn) this year. Picture: Mark Ralston/AFP via Getty Images

Johnson & Johnson’s fourth-quarter sales beat expectations, led by strong growth for several newer cancer treatments, while issuing higher-than-expected 2026 guidance despite a recent deal with the US administration to give discounts on some of the company’s key drugs.

Sales are projected to be in a range of between $100bn to €101bn (€85bn to €86bn) this year — above the average of analyst estimates. The company sees adjusted earnings of as much as $11.63 a share for the year. J&J said fourth-quarter earnings of $2.46 a share excluding certain items were reduced by 10c due to the company’s $3.05bn (€2.6bn) deal to buy Halda Therapeutics.